Welcome to our dedicated page for BIOAB news (Ticker: BIOAB), a resource for investors and traders seeking the latest updates and insights on BIOAB stock.
The BIOAB news page on Stock Titan provides updates and press releases related to BioArctic AB, a Swedish research-based biopharma company focused on neurodegenerative diseases. Much of the company’s news centers on its antibody Leqembi (lecanemab) for early Alzheimer’s disease and its long-term collaboration with Eisai and other partners.
Investors and followers of BIOAB can find news about clinical data presentations, such as new analyses from Phase 3 studies, long-term treatment findings, and real-world evidence from registries and observational studies. Recent communications highlight presentations at scientific meetings like the Clinical Trials on Alzheimer’s Disease (CTAD) conference, where Eisai, as BioArctic’s partner, shares results on lecanemab’s long-term effects, safety, and different administration approaches, including subcutaneous and intravenous dosing.
Company news also covers the broader development program around lecanemab, including ongoing studies like AHEAD 3-45 in preclinical Alzheimer’s disease and the Tau NexGen clinical study for dominantly inherited Alzheimer’s disease. Updates may describe how lecanemab targets aggregated soluble protofibril and insoluble forms of amyloid-beta and discuss findings from real-world clinical practice and post-marketing studies.
By following this news page, readers can monitor how BioArctic’s collaborations, clinical programs and technology platforms, such as its BrainTransporter™ technology, progress over time. This makes the BIOAB news feed a useful reference for those tracking scientific, clinical and partnership developments related to BioArctic and its Alzheimer’s and other neurodegenerative disease projects.
BioArctic (Nasdaq: B) announced that partner Eisai will present new data on lecanemab (Leqembi) at the CTAD conference in San Diego, Dec 1–4, 2025.
Presentations cover long‑term treatment analyses, estimated time savings over 10 years, safety and pharmacokinetics for a subcutaneous initiation option, effects on soluble Aβ protofibrils, and real‑world registry findings including ALZ‑NET and a Japanese post‑marketing study.
